SNY: サノフィ

SNY News

• 13:45 Regeneron: Is The Market Undervaluing Its Growth Potential (NASDAQ:REGN)
• 19:26 Sanofi: Why The Market Seems To Be Overpricing Pipeline Risk (NASDAQ:SNY)
• 13:25 GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth
• 12:38 Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push
• 05:19 Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here’s What You Should Know
• 20:09 Recursion: REC-4881 End 2026 Program Update And Collaboration Candidates In Play (RXRX)
• 17:43 Sanofi Must Set Record Straight on Rival Flu Shot Under EU Antitrust Deal
• 16:05 Sanofi Inks Letter Of Intent With pan-Canadian Pharmaceutical Alliance For Dupixent For Four Additional Indications
• 15:31 Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?
• 12:56 What to Expect From Regeneron Pharmaceuticals' Next Quarterly Earnings Report
• 12:42 Recursion Announces Sanofi Option Of First Immunology Drug Candidate, Triggering $10M Milestone Payment And Potential Phase 1 Trials In 2027
• 15:09 Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?
• 12:00 Why A Biotech M&A Wave May Hit This Winter
• 15:07 TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia
• 12:35 5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% Plus (October 2026)
• 20:55 Teva: 'Hold' On FDA Approval Of Weltruza And Pivot To Growth Strategy (TEVA)
• 11:58 Regeneron Pharmaceuticals, Sanofi Amend License, Collaboration Agreement To Jointly Develop, Commercialize Four New Regeneron-Invented Antibodies; Regeneron Anticipates Pre-Tax Acquired In-Process Research And Development Charge Of ~$22M
• 18:21 An $8 Billion Reason Why Regeneron Stock Is in Focus
• 12:45 Sanofi, Regeneron Expand Immunology Alliance With New Antibodies
• 15:07 Sanofi Deepens 20-Year Drug Development Pact With Regeneron, Pledges Up to $8 Billion
• 05:48 Sanofi Expands Regeneron Alliance With Four Long-Acting Antibodies, Paying $1B Upfront With Up To $7B In Milestones; Costs And Profits Shared Equally
• 17:58 3 Beaten-Down Blue-Chip Stocks to Buy Now on the Dip
• 16:40 Amazon, Walmart Surplus Auctioneer Climbs Toward A Breakout; Stock Up 45%
• 11:50 Teva's Branded Drugs Take Center Stage in Its Growth Strategy